Swift Run Capital Management LLC Maintains Position in Becton, Dickinson and Company (BDX)

Swift Run Capital Management LLC held its stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,130 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Swift Run Capital Management LLC’s holdings in Becton, Dickinson and were worth $220,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of BDX. Waldron LP bought a new stake in Becton, Dickinson and during the 1st quarter valued at approximately $383,000. Parsons Capital Management Inc. RI raised its stake in Becton, Dickinson and by 7.1% during the 1st quarter. Parsons Capital Management Inc. RI now owns 5,024 shares of the medical instruments supplier’s stock valued at $922,000 after purchasing an additional 335 shares during the period. Beaumont Financial Partners LLC bought a new stake in Becton, Dickinson and during the 1st quarter valued at approximately $342,000. Verity & Verity LLC raised its stake in Becton, Dickinson and by 2.6% during the 1st quarter. Verity & Verity LLC now owns 28,703 shares of the medical instruments supplier’s stock valued at $5,265,000 after purchasing an additional 736 shares during the period. Finally, North Star Investment Management Corp. raised its stake in Becton, Dickinson and by 3.4% during the 1st quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after purchasing an additional 18 shares during the period. 87.43% of the stock is currently owned by institutional investors.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 in the last three months. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) opened at 195.34 on Friday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock has a market cap of $44.45 billion, a PE ratio of 56.57 and a beta of 1.06. The firm’s 50-day moving average price is $199.43 and its 200 day moving average price is $191.33.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the prior year, the firm earned $2.35 earnings per share. The business’s revenue was down 5.1% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.49%. Becton, Dickinson and’s payout ratio is currently 83.43%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/16/swift-run-capital-management-llc-maintains-position-in-becton-dickinson-and-company-bdx.html.

Several analysts recently issued reports on the company. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $196.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply